February 2005
Worldwide Biotech;Feb2005, Vol. 17 Issue 2, p5
Trade Publication
Reports on the completion of the European Mutual Recognition Procedure for the approval of WinRho SDF from Cangene in ten European countries. Role of the WinRho SDF in the treatment of hemolytic disease of newborn and clotting disorder; Impact of the approval on the expansion plans of the company; Purpose of the procedure.


Related Articles

  • Conquering erythroblastosis fetalis: 50 years of RhIG. Vossoughi, Sarah; Spitalnik, Steven L. // Transfusion;Jul2019, Vol. 59 Issue 7, p2195 

    No abstract available.

  • VariZIG OK'd for Chickenpox.  // Monthly Prescribing Reference;Jan2013, Vol. 29 Issue 1, pA15 

    The article offers information on the approval of a drug VariZIG from Cangene Corp. for the treatment of chicken pox.

  • New Anthrax Treatment Approved. Rubin, Rita // JAMA: Journal of the American Medical Association;5/5/2015, Vol. 313 Issue 17, p1704 

    The article reports on the approval by the U.S. Food and Drug Administration (FDA) of anthrax immune globulin intravenous, sold under the brand name Anthrasil, as a treatment for anthrax to be used with antibacterial agents and notes it is manufactured by Canadian pharmaceutical company Cangene.

  • Significance of fetal hemoglobin-containing erythroblasts (F blasts) and the F blast/F cell ratio in myelodysplastic syndromes. Choi, J.W.; Kim, Y. // Leukemia (08876924);Aug2002, Vol. 16 Issue 8, p1478 

    To investigate the relationship between the fetal hemoglobincontaining erythroblasts (F blasts) and apoptosis in myelodysplastic syndromes (MDS), we immunohistochemically assessed F blasts, F cells, and apoptosis in 137 patients with MDS. A marked increase in the number of F blasts in the bone...

  • Successfull Perinatal Management of Hydrops Fetalis Due to Hemolytic Disease Associated with D-- -- Maternal Phenotype. Aref, K.; Boctor, F.N.; Pandle, S.; Uehlinger, J.; Manning, F.; Eglowstein, M.; Mallozzi, A.; Bebbington, M.; Weinberg, G.; Rosen, O.; Raab, C.; Brion, L.P. // Journal of Perinatology;Dec2002, Vol. 22 Issue 8, p667 

    Focuses on the successful perinatal management of hydrops fetalis due to hemolytic disease associated with D-- maternal phenotype. Efficacy of intravenous immunoglobulins in treating hemolytic disease of the newborn infant; Serial assessments of fetal ultrasonogram.

  • Fetal Sex and Hemolytic Disease from Maternal Red-Cell Alloimmunization. Ulm, Barbara; Ulm, Martin R.; Panzer, Simon // New England Journal of Medicine;06/04/98, Vol. 338 Issue 23, p1699 

    The article presents a letter to the editor about the relationship between fetal sex and hemolytic disease.

  • "ABO Hemolytic Disease" Smith, David W.; Stevenson, David K. // Clinical Pediatrics;Feb1986, Vol. 25 Issue 2, p116 

    Presents a letter to the editor about newborn screening for ABO hemolytic disease.

  • Rhesus immunisation during pregnancy: the case for antenatal anti-D. Clarke, Cyril; Whitfield, A.G.W. // British Medical Journal;3/29/1980, Vol. 280 Issue 6218, p903 

    Reports the case of infant mortality from rhesus hemolytic disease. Increase in the volume of bilirubin concentration; Detection of anti-D at delivery; Failure of anti-D prophylaxis.

  • Hemolytic disease of the newborn: lowest achievable incidence rates. Hensleigh, Paul A.; Rennie, Drummond; Dan, Bruce B.; Hensleigh, P A // JAMA: Journal of the American Medical Association;11/13/91, Vol. 266 Issue 18, p2562 

    Presents a letter to the editor in response to the article 'Epidemiology of Rh Hemolytic Disease of the Newborn in the U.S.,' by Gilberto F. Chavez et al., in a 1991 issue of the 'Journal of the American Medical Association.'


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics